These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 15372179)

  • 1. [Cost-effectiveness of atorvastatin in the early treatment of acute coronary syndromes in Germany based on the MIRACL study].
    Lange AP; Szucs TD
    Med Klin (Munich); 2004 Sep; 99(9):500-5. PubMed ID: 15372179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes in Spain.
    Gómez-Gerique JA; Casciano R; Stern L; Rejas J
    Eur J Health Econ; 2004 Oct; 5(3):278-84. PubMed ID: 15714350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pharmacoeconomic evaluation of aggressive cholesterol lowering in Sweden.
    Olsson A; Casciano R; Stern L; Svangren P
    Int J Cardiol; 2004 Jul; 96(1):51-7. PubMed ID: 15203261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pharmacoeconomic evaluation of the Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study in the United Kingdom.
    Buller N; Gillen D; Casciano R; Doyle J; Wilson K
    Pharmacoeconomics; 2003; 21 Suppl 1():25-32. PubMed ID: 12648032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes.
    Schwartz GG; Ganz P; Waters D; Arikian S
    Am J Cardiol; 2003 Nov; 92(9):1109-12. PubMed ID: 14583367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
    Kinlay S; Schwartz GG; Olsson AG; Rifai N; Sasiela WJ; Szarek M; Ganz P; Libby P;
    Circulation; 2004 Jul; 110(4):386-91. PubMed ID: 15262833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cost-effectiveness of atorvastatin for the prevention of coronary disease. An analysis of the ASCOT study].
    Szucs TD; Klose G; Düsing R
    Dtsch Med Wochenschr; 2004 Jun; 129(25-26):1420-4. PubMed ID: 15213873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic impacts attributable to the early clinical benefit of atorvastatin therapy--a US managed care perspective.
    Straka RJ; Mamdani M; Damen J; Kuntze CE; Liu LZ; Botteman MF; Koren MJ
    Curr Med Res Opin; 2007 Jul; 23(7):1517-29. PubMed ID: 17535539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction.
    Schwartz GG; Oliver MF; Ezekowitz MD; Ganz P; Waters D; Kane JP; Texter M; Pressler ML; Black D; Chaitman BR; Olsson AG
    Am J Cardiol; 1998 Mar; 81(5):578-81. PubMed ID: 9514453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
    Schwartz GG; Olsson AG; Ezekowitz MD; Ganz P; Oliver MF; Waters D; Zeiher A; Chaitman BR; Leslie S; Stern T;
    JAMA; 2001 Apr; 285(13):1711-8. PubMed ID: 11277825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pharmacoeconomic evaluation of the myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) study in Canada.
    Casciano R; Tarride JE; Breton MC; Stern L; Langer A
    Can J Clin Pharmacol; 2004; 11(1):e179-90. PubMed ID: 15300960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy.
    Waters DD; Schwartz GG; Olsson AG; Zeiher A; Oliver MF; Ganz P; Ezekowitz M; Chaitman BR; Leslie SJ; Stern T;
    Circulation; 2002 Sep; 106(13):1690-5. PubMed ID: 12270864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.
    Plosker GL; Lyseng-Williamson KA
    Pharmacoeconomics; 2007; 25(12):1031-53. PubMed ID: 18047388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study.
    Taylor DC; Pandya A; Thompson D; Chu P; Graff J; Shepherd J; Wenger N; Greten H; Carmena R; Drummond M; Weinstein MC
    Eur J Health Econ; 2009 Jul; 10(3):255-65. PubMed ID: 18800232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Costs and cost-effectiveness of Eptifibatide in the treatment of coronary ischemic syndromes. An analysis based on the PURSUIT study].
    Szucs TD; Schwenkglenks M; Berger K; Karsch K
    Z Kardiol; 2003 Mar; 92(3):236-44. PubMed ID: 12658471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale and design of the Myocardial Ischemia Reduction With Aggressive Cholesterol lowering (MIRACL) Study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction.
    Ghali JK
    Am J Cardiol; 1998 Sep; 82(5):703. PubMed ID: 9732912
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD; Rattinger GB; Kuznik A; Koren MJ
    Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
    Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
    Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.
    Olsson AG; Schwartz GG; Szarek M; Sasiela WJ; Ezekowitz MD; Ganz P; Oliver MF; Waters D; Zeiher A
    Eur Heart J; 2005 May; 26(9):890-6. PubMed ID: 15764620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.